|
US2010215699A1
|
|
Lactoferrin as a radioprotective agent
|
|
WO2007150049A2
|
|
Lactoferrin as a radioprotective agent
|
|
WO2007022537A2
|
|
Use of lactoferrin as a chemokine and a chemotactic modulator
|
|
WO2006047744A2
|
|
Compositions of lactoferrin related peptides and uses thereof
|
|
US2005075277A1
|
|
Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
|
|
WO2005046571A2
|
|
Lactoferrin as an adjuvant in cancer vaccines
|
|
US7034126B2
|
|
Lactoferrin in the treatment of diabetes mellitus
|
|
AU2003293500A1
|
|
Lactoferrin in the reduction of pain
|
|
AU2003296447A8
|
|
Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
|
|
CN1744907A
|
|
Oral lactoferrin in the treatment of sepsis
|
|
AU2003298906A1
|
|
Oral lactoferrin in the treatment of sepsis
|
|
US7026295B2
|
|
Lactoferrin in the reduction of circulating cholesterol, vascular inflammation, atherosclerosis and cardiovascular disease
|
|
US7524814B2
|
|
Lactoferrin compositions and methods of wound treatment
|
|
WO03099207A2
|
|
Oral lactoferrin in the treatment of respiratory disorders
|
|
AU2003273182A1
|
|
Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
|
|
US6399570B1
|
|
Antimicrobial/endotoxin neutralizing polypeptide
|
|
NZ500712A
|
|
Use of a lactoferin product to inhibit the inflammatory activity of interleukin-1 beta in the treatment of allergen-induced inflammatory disorders
|
